JTEC Corporation

3446.T
Medical Instruments & Supplies
2026/07/24 Updated
Market Cap: $53.5M (¥8.8B)
Stock Price: $9.06 (¥1,482)
Exchange Rate: 1 USD = ¥163.67

Notice of Revision to Full-Year Consolidated Earnings Forecast

Full-year consolidated earnings forecast for the fiscal year ending June 2026 revised downward. Net sales reduced from previous forecast of 2,655 million to 1,955 million (down 26.3%), operating income from 278 million to 73 million (down 73.6%), ordinary income from 274 million to 85 million (down 69.0%), net income attributable to owners of the parent from 172 million to 59 million (down 65.5%). The factors include shortfalls in sales plans and delays in next-generation products across Optical, Life Science & Instrumentation, and Other Electronics segments, leading to difficult-to-attain targets.

Importance:
Page Updated: July 10, 2026
IR Disclosure Date: July 10, 2026

Key Figures

  • Sales: 1,955 million (from previous forecast 2,655 million, down 26.3%)
  • Operating income: 73 million (from previous forecast 278 million, down 73.6%)
  • Net income attributable to owners of the parent: 59 million (from previous forecast 172 million, down 65.5%)

AI要約

Key points of performance

In today's board meeting, we revised downward the full-year consolidated earnings forecast for the fiscal year ending June 2026. The primary factors are material issues and design changes causing delays in the Optical business, delays in next-generation processing and grinding equipment in Life Science & Instrumentation, and underachievement in sales plans in Electronic Science. Net sales are expected to decline 26.3%, with all profit measures significantly below the previous forecast.

Impact by segment and outlook

The Optical business faces delays due to material processing defects and design changes. Life Science & Instrumentation suffers from delayed sales of the next-generation processing and polishing equipment. Other Electronics also underperforms against plans. Although selling, general and administrative expenses have been cut by about 15.3%, overall profitability remains challenged. For a recovery, progress on individual projects and improved product sales planning are essential.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

J-Tech Corporation

Company overview · Stock price · Financial data · All IR

View company page →